Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,356 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Gene Expression Clear all
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

NCT06682793
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer), Cancer, Colon Cancer, Rectal Cancer, Lung Cancer, CRC, Head and Neck Squamous Cell Cancer, HNSCC, Renal Cell Carcinoma, RCC, Kidney Cancer, Triple Negative Breast Cancer, TNBC, Colorectal Adenocarcinoma
Interventions
A2B395, xT CDx with HLA-LOH assay
Biological · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
10
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer

NCT00002919
View directory record Official record
Conditions
Bladder Cancer
Interventions
filgrastim, cisplatin, doxorubicin hydrochloride, methotrexate, vinblastine sulfate, conventional surgery
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 19, 2026, 5:57 PM EDT
Recruiting Not applicable Interventional

Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer

NCT06849518
View directory record Official record
Conditions
Lung Cancer (NSCLC)
Interventions
Circulogene liquid biopsy testing
Diagnostic Test
Lead sponsor
Ballad Health
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kingsport, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 19, 2026, 5:57 PM EDT
Completed No phase listed Observational

Finding Predictors of Side Effects to Chemoradiation Treatment in Elderly Patients With Head and Neck Cancer

NCT01688323
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Collect Blood and Survey Instruments
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
65 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer

NCT00588003
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, Placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
45 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 19, 2026, 5:57 PM EDT
Completed No phase listed Observational

Calcium Channel Splice Variant Expression in Cardiovascular Disease and Aging

NCT00251615
View directory record Official record
Conditions
Atherosclerosis
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
21 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Oct 19, 2026, 5:57 PM EDT
Withdrawn Phase 1 Interventional

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

NCT01332279
View directory record Official record
Conditions
Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Tongue Cancer
Interventions
everolimus, erlotinib hydrochloride, biopsy, laboratory biomarker analysis, immunohistochemistry staining method, polyacrylamide gel electrophoresis, pharmacological study, external beam radiation therapy, microarray analysis
Drug · Procedure · Other + 2 more
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 19, 2026, 5:57 PM EDT
Withdrawn No phase listed Observational

Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy (PRX32)

NCT03296124
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 19, 2026, 5:57 PM EDT
Not yet recruiting No phase listed Observational

Safety and Outcomes of MUSE Stem Cell Therapy in Individuals With Traumatic Brain Injury

NCT07326059
View directory record Official record
Conditions
Traumatic Brain Injury, Traumatic Brain Injury (TBI) Patients, Traumatic Brain Injury (TBI); Concussion, Initial Encounter, Traumatic Brain Injury (TBI); Concussion, Subsequent Encounter, Traumatic Brain Injury With Brief Loss of Consciousness, Traumatic Brain Injury With Persistent Cognitive Deficits
Interventions
MUSE Stem Cell Therapy
Biological
Lead sponsor
Healing Hope International
Other
Eligibility
6 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2036
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 19, 2026, 5:57 PM EDT
Withdrawn Early Phase 1 Interventional

ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer

NCT00993642
View directory record Official record
Conditions
Breast Cancer
Interventions
Panobinostat (LBH589)
Drug
Lead sponsor
Tulane University Health Sciences Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 19, 2026, 5:57 PM EDT
Completed No phase listed Observational

Impact of Hydrocortisone Administration on White Blood Cell Gene Expression in Patients With Severe Sepsis

NCT00185783
View directory record Official record
Conditions
Sepsis, Relative Adrenal Insufficiency
Interventions
Hydrocortisone Administration (Standard of Care Therapy)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2011 · Synced Oct 19, 2026, 5:57 PM EDT
Completed No phase listed Observational

Emotional Communication Disorders in Cerebellar Disease

NCT02106819
View directory record Official record
Conditions
Cerebellar Diseases
Interventions
Testing of emotional communication ability, magnetic resonance imaging (MRI) of the brain
Behavioral · Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Not applicable Interventional

Characterization of Rectal Cancer Hypoxia Using pO2 Histography and Immunohistochemistry for Hypoxia-Related Proteins

NCT01189877
View directory record Official record
Conditions
Rectal Cancer
Interventions
Eppendorf hypoximeter
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 89 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 19, 2026, 5:57 PM EDT
Completed No phase listed Observational

Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)

NCT03189875
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Standard of Care
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
31
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 1Phase 2 Interventional

COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.

NCT04570839
View directory record Official record
Conditions
Endometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer
Interventions
COM701 in combination with BMS-986207 and nivolumab.
Drug
Lead sponsor
Compugen Ltd
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
9
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 19, 2026, 5:57 PM EDT
Completed No phase listed Observational

Effects of Epidermal Growth Factor Receptor Inhibitor Therapy in the Skin of Cancer Patients

NCT00483457
View directory record Official record
Conditions
Solid Tumor
Interventions
enzyme inhibitor therapy, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 19, 2026, 5:57 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression

NCT05163041
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BT7480, Nivolumab
Drug
Lead sponsor
BicycleTx Limited
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Iowa City, Iowa • New York, New York • Cleveland, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 19, 2026, 5:57 PM EDT
Terminated Early Phase 1 Interventional

Effects of Vitamin D on Renin Expression in Hypertensive Patients

NCT00585442
View directory record Official record
Conditions
Hypertension, Vitamin D Deficiency
Interventions
calcitriol, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
55 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 27, 2016 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose

NCT01300988
View directory record Official record
Conditions
HIV Infection
Interventions
Aprepitant, Aprepitant placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

NCT00816283
View directory record Official record
Conditions
Leukemia
Interventions
dasatinib, vorinostat, cytogenetic analysis, gene expression analysis, mutation analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2012 · Synced Oct 19, 2026, 5:57 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway

NCT06320951
View directory record Official record
Conditions
Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease, Metabolism, Energy Expenditure, Obesity
Interventions
Vericiguat 10 MG, Placebo, Insulin Sensitivity Test, Resting Energy and Exercise Energy Expenditure Assessment, White Adipose Tissue Biopsy, MRI-PET Scan for Brown Adipose Tissue Volume Assessment
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

Gene Expression and Tolerability Study of NV1FGF in Patients With Peripheral Artery Occlusive Disease Planned to Undergo Major Amputation

NCT01157143
View directory record Official record
Conditions
Peripheral Arterial Occlusive Disease
Interventions
XRP0038 (NV1FGF)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 5, 2010 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours

NCT03008018
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
KA2507
Drug
Lead sponsor
Karus Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Early Phase 1 Interventional

Topical Itraconazole in Treating Patients With Basal Cell Cancer

NCT02735356
View directory record Official record
Conditions
Skin Basal Cell Carcinoma
Interventions
Itraconazole, Placebo
Drug · Other
Lead sponsor
Jean Yuh Tang
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Oct 19, 2026, 5:57 PM EDT